Artificial intelligence is transforming genomic medicine. But the gap between public perception and clinical reality is significant.
Artificial intelligence and genomics have become inseparable in public discourse. Headlines regularly announce that AI has "diagnosed cancer from a blood test" or "predicted Alzheimer's from a genome scan." The reality is more nuanced — and considerably more important to understand clearly if you are considering genomic testing.
This article explains exactly what AI does in the GeneAI interpretation workflow, why the boundaries matter as much as the capabilities, and how to think critically about any AI-assisted genomic result.
What AI Does in Genomic Analysis
The human genome contains approximately 3.2 billion base pairs. Even with high-quality sequencing, a whole genome produces millions of variants — positions where your DNA differs from the reference genome. The vast majority of these are benign polymorphisms. A smaller number are clinically significant. An even smaller number are directly relevant to the question your test was designed to answer.
The challenge of genomic analysis is not detecting variants — sequencing technology does this well. The challenge is prioritisation and interpretation: identifying which variants, out of millions, are likely to be clinically relevant, and what the current evidence says about them.
This is where AI plays a genuine and valuable role.
Variant Prioritisation
The GeneAI Intelligence Engine applies a combination of rule-based classification and machine learning to rank identified variants by their likelihood of clinical significance. It uses established frameworks — primarily the ACMG/AMP variant classification guidelines — as its baseline, and applies population frequency data from gnomAD, pathogenicity predictions, and in silico functional modelling to score each variant.
The result is a ranked list of variants that focuses clinical attention on the candidates most likely to be meaningful — rather than requiring a human reviewer to manually assess thousands of candidates.
Research Cross-referencing
For each prioritised variant, the engine cross-references published literature (PubMed, OMIM), clinical databases (ClinVar, HGMD where licensed), and current peer-reviewed evidence. It surfaces the state of knowledge about each variant — how many cases have been reported, what clinical presentations have been associated, what the strength of evidence for pathogenicity is.
This cross-referencing would take a human analyst hours per variant. The AI engine does it in seconds, consistently, at scale.
Report Structuring
The final AI function is structuring. Raw variant data is not readable by a patient or, in many cases, by a non-specialist clinician. The GeneAI engine compiles findings into a structured, legible report — with a plain-language patient summary, a technically-detailed findings section, and full supporting data in an appendix.
What AI Cannot Do
This is where precision matters.
The AI engine does not diagnose. Diagnosis is a clinical act that requires integration of symptom history, physical examination findings, family history, imaging data, and the genomic result within a holistic clinical assessment. A variant flagged as "likely pathogenic" by the AI engine is a data point in that process — not a conclusion.
The AI engine does not prescribe. It generates no treatment recommendations, no drug selections, no intervention plans. Clinical decisions are exclusively the domain of qualified healthcare professionals.
The AI engine does not replace a clinical geneticist. For complex cases — particularly undiagnosed rare disease or multi-gene presentations — the interpretation of a specialist human geneticist is not only valuable but necessary. GeneAI facilitates access to such specialists through its referral pathway; it does not simulate their expertise.
Why the Boundaries Matter
AI misuse in medicine is a genuine risk. Direct-to-consumer genomic testing companies have, in some cases, allowed customers to interpret AI-generated variant results without clinical context — leading to unnecessary procedures, significant anxiety, and, in documented cases, harmful decisions based on misunderstood outputs.
GeneAI's approach is different by design. Every AI output on the platform is explicitly labelled as informational. No output is presented as a clinical conclusion. The report is designed to prepare a patient for a clinical conversation — not to replace one.
This is not regulatory caution. It reflects the actual state of the science. Genomic variant interpretation remains genuinely uncertain in many cases. Variants of uncertain significance are common. The same variant can present differently in different individuals. Population-specific differences in variant penetrance are real.
Any AI system that presents certainty where the underlying science contains uncertainty is not serving the patient — it is misrepresenting the science.
The Right Question
The right question about AI in genomic medicine is not "can AI diagnose genetic conditions?" It can, in some limited contexts, contribute meaningfully to diagnostic workflows. The right question is: "does the AI system operate within the appropriate boundaries, with explicit transparency about what it knows and does not know, in a governance framework that protects the patient?"
That is the question GeneAI has built its entire architecture to answer in the affirmative.